An overview of radiation-induced heart disease.

IF 1.8 Q3 ONCOLOGY Radiation Oncology Journal Pub Date : 2022-06-01 Epub Date: 2022-06-21 DOI:10.3857/roj.2021.00766
Samer Ellahham, Amani Khalouf, Mohammed Elkhazendar, Nour Dababo, Yosef Manla
{"title":"An overview of radiation-induced heart disease.","authors":"Samer Ellahham,&nbsp;Amani Khalouf,&nbsp;Mohammed Elkhazendar,&nbsp;Nour Dababo,&nbsp;Yosef Manla","doi":"10.3857/roj.2021.00766","DOIUrl":null,"url":null,"abstract":"<p><p>Radiation therapy (RT) has dramatically improved cancer survival, leading to several inevitable complications. Unintentional irradiation of the heart can lead to radiation-induced heart disease (RIHD), including cardiomyopathy, pericarditis, coronary artery disease, valvular heart disease, and conduction system abnormalities. Furthermore, the development of RIHD is aggravated with the addition of chemotherapy. The screening, diagnosis, and follow-up for RIHD in patients who have undergone RT are described by the consensus guidelines from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). There is compelling evidence that chest RT can increase the risk of heart disease. Although the prevalence and severity of RIHD are likely to be reduced with modern RT techniques, the incidence of RIHD is expected to rise in cancer survivors who have been treated with old RT regimens. However, there remains a gap between guidelines and clinical practice. Currently, therapeutic modalities followed in the treatment of RIHD are similar to the non-irradiated population. Preventive measures mainly reduce the radiation dose and radiation volume of the heart. There is no concrete evidence to endorse the preventive role of statins, angiotensin-converting enzyme inhibitors, and antioxidants. This review summarizes the current evidence of RIHD subtypes and risk factors and suggests screening regimens, diagnosis, treatment, and preventive approaches.</p>","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":"40 2","pages":"89-102"},"PeriodicalIF":1.8000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/16/80/roj-2021-00766.PMC9262704.pdf","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiation Oncology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3857/roj.2021.00766","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/6/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 8

Abstract

Radiation therapy (RT) has dramatically improved cancer survival, leading to several inevitable complications. Unintentional irradiation of the heart can lead to radiation-induced heart disease (RIHD), including cardiomyopathy, pericarditis, coronary artery disease, valvular heart disease, and conduction system abnormalities. Furthermore, the development of RIHD is aggravated with the addition of chemotherapy. The screening, diagnosis, and follow-up for RIHD in patients who have undergone RT are described by the consensus guidelines from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). There is compelling evidence that chest RT can increase the risk of heart disease. Although the prevalence and severity of RIHD are likely to be reduced with modern RT techniques, the incidence of RIHD is expected to rise in cancer survivors who have been treated with old RT regimens. However, there remains a gap between guidelines and clinical practice. Currently, therapeutic modalities followed in the treatment of RIHD are similar to the non-irradiated population. Preventive measures mainly reduce the radiation dose and radiation volume of the heart. There is no concrete evidence to endorse the preventive role of statins, angiotensin-converting enzyme inhibitors, and antioxidants. This review summarizes the current evidence of RIHD subtypes and risk factors and suggests screening regimens, diagnosis, treatment, and preventive approaches.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
辐射诱发心脏病的综述。
放射治疗(RT)显著提高了癌症的生存率,导致了一些不可避免的并发症。无意中照射心脏会导致放射性心脏病(RIHD),包括心肌病、心包炎、冠状动脉疾病、瓣膜性心脏病和传导系统异常。此外,RIHD的发展随着化疗的增加而加剧。欧洲心血管成像协会(EACVI)和美国超声心动图学会(ASE)的共识指南描述了接受RT的患者RIHD的筛查、诊断和随访。有令人信服的证据表明胸部RT会增加患心脏病的风险。尽管现代RT技术可能会降低RIHD的患病率和严重程度,但接受旧RT方案治疗的癌症幸存者的RIHD发病率预计会上升。然而,指南和临床实践之间仍然存在差距。目前,RIHD的治疗方法与未经照射的人群相似。预防措施主要是减少心脏的辐射剂量和辐射量。没有具体的证据支持他汀类药物、血管紧张素转换酶抑制剂和抗氧化剂的预防作用。这篇综述总结了RIHD亚型和危险因素的最新证据,并提出了筛查方案、诊断、治疗和预防方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.50
自引率
4.30%
发文量
24
期刊最新文献
Proton beam therapy as a promising option for high-risk limited stage small cell lung cancer: revealing potential of future novel agents Different approaches to target volume definition and boost delivery in surgery de-escalation clinical trial in breast cancer patients with pathological complete response Target movement according to cervical lymph node level in head and neck cancer and its clinical significance Comparison of radiotherapy techniques in patients with thymic epithelial tumor who underwent postoperative radiotherapy Pulmonary function and toxicities of proton versus photon for limited-stage small cell lung cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1